)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Indoco Remedies
Indoco Remedies (INDOCO) investor relations material
Indoco Remedies Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary27 Oct, 2026
Executive summary
Q2 FY27 consolidated revenue rose 7.4% YoY to ₹50,692 lakhs; H1 revenue grew 7.8% to ₹97,314 lakhs. Consolidated EBITDA margin was 9.2% in Q2 and 9.0% in H1.
International formulations, API and allied services grew, while domestic formulations faced seasonal weakness. Consolidated net profit was ₹1,947 lakhs in Q2, including exceptional gains.
Financial highlights
Consolidated Q2 revenue was ₹50,692 lakhs versus ₹48,467 lakhs YoY; H1 revenue was ₹97,314 lakhs versus ₹90,270 lakhs.
Standalone net revenue was ₹4,381 million, up 2% YoY; standalone revenue from operations including other operating income was ₹45,159 lakhs in Q2 and ₹86,056 lakhs in H1.
Standalone EBITDA was ₹403 million, or 9.2% of net sales, versus ₹534 million and 12.4% YoY; Q1 EBITDA was ₹422 million, or 10.3%.
Consolidated EBITDA was ₹464 million, or 9.2% of net sales, versus ₹431 million and 9.1% YoY; H1 EBITDA was ₹875 million, or 9.0%, versus ₹606 million and 6.7%.
Consolidated profit before exceptional items and tax was a loss of ₹1,295 lakhs in Q2; after exceptional items, profit before tax was ₹2,419 lakhs. Standalone Q2 net profit was ₹3,063 lakhs.
Outlook and guidance
Domestic FY27 high-single-digit growth guidance was maintained; management expects more predictable H2 sales, with seasonal portfolio weakness and divested ophthalmic sales weighing on performance.
Export revenue is expected to achieve double-digit FY27 growth, supported by regulated markets and a potential H2 catch-up in emerging markets.
Europe and UK regulated-market growth target is 20%+ over the next one to two years; emerging markets are expected to improve from Q3, with Q4 typically stronger.
H2 priorities include strengthening domestic brands, accelerating international growth, improving operating efficiency and disciplined resource allocation.
Management emphasized operational efficiency and a resilient, diversified pharmaceutical business for sustainable long-term growth.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Indoco Remedies
- Revenue topped ₹1,000 crore as export growth offset margin and PBT pressure.INDOCO
Q4 15/16 - PAT rose 43% as export growth and expanded research capabilities strengthened the outlook.INDOCOQ4 14/15
- Revenue rose 15.4% and PBT 49.1% as international growth and margins strengthened.INDOCOQ4 13/14
- Revenue advanced, but input costs and FX losses cut profit as expansion initiatives progressed.INDOCOQ4 12/13
- 9M growth was led by stronger profits, exports and new regulated-market opportunities.INDOCOQ4 07/08
- Revenue growth outpaced profits as finance costs surged; international business led expansion.INDOCOQ4 11/12
- Exports and strategic expansion lifted FY07 sales 28% to Rs.34,443 lakh.INDOCOQ4 06/07
- International sales exceeded Rs 100 crore as FY09 PAT reached Rs 31.44 crore.INDOCOQ4 08/09
- PAT rose 21.4% as international sales and manufacturing capacity expanded.INDOCOQ4 10/11
Next Indoco Remedies earnings date
Q3 26/272 Feb, 2027
Indoco Remedies
Next Indoco Remedies earnings date
Q3 26/272 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)